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cinoma. Purposes of the current study were to evaluate the changing incidence rates of
oesophageal and gastric cardia cancer, and to assess survival trends.
Patients and methods: Patients diagnosed with oesophageal adenocarcinoma (N = 12,195) or
SCC (N = 9046), or gastric cardia adenocarcinoma (N = 9900) between 1989 and 2008 in the
Netherlands were included. Changes in European Standard Population (ESP) and relative sur-
vival over time were evaluated.
Results: Incidence rates for oesophageal adenocarcinoma increased in males (+7.5%,
P < 0.001) and females (+5.2%, P < 0.001), while the incidence for oesophageal SCC remained
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J.L. Dikken et al. / European Journal of Cancer 48 (2012) 1624–1632 1625incidence for gastric cardia cancer decreased in males (1.2%, P < 0.006), and remained stable
in females (0.2%, P = 0.7).
Five-year survival for both M0 and M1 oesophageal carcinoma doubled over the last 20 years.
No signiﬁcant changes in survival were found for M0 and M1 gastric cardia carcinoma.
Discussion: In the Netherlands, a rising incidence is seen for oesophageal adenocarcinoma, but
not for gastric cardia adenocarcinoma. This ﬁnding most likely reﬂects true changes in disease
burden, rather than being the result of changes in diagnosis or classiﬁcation. The increased
survival for oesophageal carcinoma can be attributed to centralisation of surgery, and an
increased use of multimodality therapy, factors hardly acknowledged for gastric cancer.
 2012 Elsevier Ltd.Open access under the Elsevier OA license. 1. Introduction
Oesophageal and gastric cancers are, respectively, the
sixth and second causes of cancer death worldwide, with
an estimated 500,000 new cases of oesophageal cancer
and 1 million new cases of gastric cancer each year.1
Oesophageal cancer is primarily composed of two his-
tological types, adenocarcinoma and squamous cell car-
cinoma (SCC), each with a distinct aetiology and speciﬁc
risk factors.2 Subtypes of gastric cancer are often based
on topology, distinguishing cardia and non-cardia gas-
tric cancers. Most gastric cancers are adenocarcinomas.
Worldwide, there has been a marked increase in the
incidence of oesophageal cancer over the last decades,
which is mainly attributed to an increase in the incidence
of adenocarcinoma of the oesophagus in North Amer-
ica,3,4 Europe5 and Japan.6 The incidence of SCC of
the oesophagus has remained stable or is declining.3,5
For gastric cardia cancer, two studies have reported a
rising incidence in the United States in the seventies
and eighties, while the incidence since then has stabi-
lised.4,7 In the Netherlands, a rising incidence of adeno-
carcinoma of the oesophagus has been reported as well
during from 1989 to 2003, while the incidence of oesoph-
ageal SCC hardly increased, and gastric cardia cancer
incidence rates were declining.8,9 However, these data
did not include a comprehensive analysis of incidence
and survival for oesophageal adenocarcinoma, oesopha-
geal SCC and gastric cardia adenocarcinoma.
The ﬁrst purpose of the current study was to give an
update on incidence rates and stage distribution for
oesophageal adenocarcinoma and SCC, and gastric
cardia adenocarcinoma in the Netherlands from 1989
to 2008. The second purpose was to evaluate survival
patterns for these cancers during the same period.
2. Patients and methods
2.1. The Netherlands Cancer Registry
Data were obtained from the Netherlands Cancer
Registry (NCR), in which data are collected on all newly
diagnosed malignancies in the Netherlands, a country of
16.7 million inhabitants. The NCR receives data from
eight regional cancer registries, covering all hospitalsin the Netherlands. Information on patient and tumour
characteristics and treatment is routinely collected by
trained registrars who extract this information from
the hospital records 6–18 months after diagnosis.
Topography and morphology are coded according to
the International Classiﬁcation of Diseases for Oncol-
ogy (ICD-O),10 based on information from the medical
ﬁles, including the pathology report. Tumours are
staged according to the International Union against
Cancer (UICC) TNM classiﬁcation. Until December
1996, the UICC 4th edition was used,11 from 1997 until
2001 the UICC 5th edition was used,12 and as of
January 2002, all tumours were coded according to the
UICC 6th edition.13 For oesophageal carcinoma, the
4th, 5th, and 6th UICC TNM classiﬁcations were not
diﬀerent, except for a minor modiﬁcation in the 5th
edition with the introduction of the M1a and M1b
classiﬁcation. For gastric cardia cancer, starting with
the 5th edition, nodal (N) status was based on the
absolute number of positive lymph nodes, rather than
the location of the lymph node metastases. Vital status
in the NCR is extracted from the medical records or is
obtained by record linkage with the Dutch Central
Bureau of Statistics, which registers all deceased persons
in the Netherlands. As the NCR does not capture the
cause of death, mortality rates were extracted from the
Dutch Central Bureau of Statistics, separately for
oesophageal and gastric cancer. The study was approved
by the NCR Review Board.
2.2. Patients
Between January 1989 and December 2008, 22,530
cases of primary invasive oesophageal (C15.0–15.9)
and 9963 cases of primary invasive gastric cardia cancer
(C16.0) were diagnosed in the Netherlands. For the cur-
rent study, adenocarcinomas (ICD-O morphology codes
8140–8142, 8144, 8145, 8190, 8200, 8210, 8211, 8230,
8255, 8260–8263, 8310, 8130, 8180, 8481, 8490, 8510,
8560, 8570, 8573–8576) of the oesophagus or gastric car-
dia and SCCs (ICD-O morphology codes 8051, 8052,
8070–8076, 8078) of the oesophagus were selected.
Tumours with other or unknown histology (including
‘No Otherwise Speciﬁed’) of the oesophagus
(N = 1289) or gastric cardia (N = 63) were excluded,
1626 J.L. Dikken et al. / European Journal of Cancer 48 (2012) 1624–1632leaving 21,241 patients with oesophageal cancer, and
9900 patients with cardia cancer for analysis.2.3. Statistical analysis
Separate analyses were performed for oesophageal
adenocarcinoma (C15.0–15.9), oesophageal SCC
(C15.0–C15.9) and gastric cardia adenocarcinoma
(C16.0). To evaluate trends over time, the study period
was divided in four intervals of ﬁve years.
Incidence rates were calculated as the number of new
patients per 100,000 inhabitants per year, and are age-
standardised using the European Standardised Popula-
tion (ESP).14 The ESP reﬂects the incidence as if the
population of the Netherlands would have the same
age-composition as a hypothetical European popula-
tion. Changes in incidence were evaluated with the esti-
mated annual percentage change (EAPC), ﬁtting a
regression line to the natural logarithm of the rates using
calendar year as a regressor variable.15
Diﬀerences in stage distribution between the various
time-periods were calculated with a chi-square test.
Stage IV gastric cardia adenocarcinoma comprises not
only M1 disease but also locally advanced (T4N1-3,
T1-3N3) M0 disease.13 Therefore, stage IV-M0 and
stage IV-M1 gastric cardia adenocarcinomas were ana-
lysed separately.
Follow-up was complete until December 31st 2009.
Survival was calculated from the date of diagnosis until
death of any cause (event) or alive at last follow-up
(censored) by using the life-table method. Then, relative
survival was calculated correcting for age- and gender-
speciﬁc background mortality.16 Ninety-ﬁve percentage
conﬁdence intervals (CI) of survival estimates were
calculated according to:
lower boundary ¼ mean survival rate 1:96
 standard error
upper boundary ¼ mean survival rateþ 1:96
 standard error
Mortality rates were obtained directly from the Dutch
Central Bureau of Statistics as the absolute number of
deaths per 100,000. All analyses were performed with
SAS statistical software (version 9.2).3. Results
Between 1st January 1989 and 31st December 2008,
12,195 patients with oesophageal adenocarcinoma,
9046 patients with oesophageal SCC and 9900 patients
with gastric cardia adenocarcinoma were diagnosed in
the Netherlands. Patient and tumour characteristics
are summarised in Table 1. The number of males
exceeded the number of females in all three subgroups.
Median age at diagnosis was 69.6 years for oesophagealadenocarcinoma, 66.9 years for oesophageal SCC and
69.3 years for gastric cardia adenocarcinoma. The
majority (83.7%) of oesophageal adenocarcinomas were
located in the lower oesophagus (Fig. 3). Oesophageal
SCC was more evenly distributed throughout the
oesophagus.
The incidence of oesophageal adenocarcinoma
increased in males in the period 1989–2008 (Fig. 1a):
the ESP increased from 3.2 per 100,000 inhabitants per
year in 1989 to 9.9 in 2008 with an estimated annual per-
centage change (EAPC) of +7.5 (95% CI +6.8 to +8.2,
P < 0.001). In females, the ESP of oesophageal adeno-
carcinoma also increased, but to a lesser extent: from
0.7 in 1989 to 1.7 in 2008, with an EAPC of +5.2
(95% CI +4.2 to +6.2, P < 0.001). For oesophageal
SCC, no signiﬁcant change was detected in males
(EAPC 0.2, 95% CI 1.0 to 0.6, P = 0.6), while in
females the incidence slightly increased (EAPC +1.7,
95% CI +0.8 to +2.7, P = 0.001). The incidence of gas-
tric cardia carcinoma decreased over the years in males
but did not signiﬁcantly change in females (Fig. 1b): in
males, the ESP decreased from 5.7 in 1989 to 4.4 in
2008, with an EAPC of 1.2 (95% CI 2.0 to 0.4,
P = 0.006), and in females, the ESP decreased from
1.2 in 1989 to 1.0 in 2008, with an EAPC of 0.2
(95% CI 0.9 to 1.2, P = 0.7).
Diﬀerences in stage distribution were noted (all
P < 0.001), but in all three tumour types about 40% of
all tumours were diagnosed in a non-metastatic stage.
The other 60% of tumours were either staged as M1 dis-
ease, or did not have a stage group assigned. Changes in
stage distributions over the years for oesophageal ade-
nocarcinoma and SCC showed a similar pattern over
time (Figs. 2a and 2b). The percentage of patients with
an unknown stage steadily decreased, with a corre-
sponding increase in the proportion of stage IV patients.
Comparing changes in tumour location for oesophageal
adenocarcinoma versus SCC, there was a relative
increase in distally located tumours for adenocarcinoma
(77.2–87.7%), without major changes in the distribution
of SCCs (Fig. 3a and b).
For gastric cardia adenocarcinoma (Fig. 2c), the pro-
portion of patients with no stage assigned also
decreased, but this was less prominent (from 19.8% to
15.0%). With the incorporation of the absolute number
of metastatic lymph nodes into the TNM classiﬁcation
as of 1997, diﬀerences in stage distribution for gastric
tumours might very well reﬂect a staging diﬀerence
rather than a true shift in stage distribution.
Mortality rates per 100,000 inhabitants in the
Netherlands increased for oesophageal carcinoma, both
for males (from 6.8 to 13.9) and females (3.1–5.1).
Mortality rates for gastric cancer decreased for males
(18.6–10.7) and females (11.5–6.6). Survival estimates
for oesophageal and gastric cardia carcinoma are shown
in Table 2. Five-year relative survival signiﬁcantly
Table 1
Patient and tumour characteristics
Oesophageal
adenocarcinoma
(C15.0–15.9)
Oesophageal
SCC
(C15.0–15.9)
Gastric cardia
adenocarcinoma
(C16.0)
N % N % N %
Total 12,195 100 9046 100 9900 100
Sex
Male 9566 78.4 5429 60.0 7640 77.2
Female 2629 21.6 3617 40.0 2260 22.8
Age at diagnosis (years)
<60 2952 24.2 2661 29.4 2452 24.8
60–74 5124 42.0 4062 44.9 4380 44.2
>74 4119 33.8 2323 25.7 3068 40.0
Tumour location
Cervical oesophagus 52 0.4 400 4.4
Intrathoracic upper 1/3 182 1.5 1106 12.2
Intrathoracic middle 1/3 1003 8.2 3148 34.8
Intrathoracic lower 1/3 10,211 83.7 3509 38.8
Other/unknown 747 6.1 883 9.8
Gastric cardia 9900 100
Diﬀerentiation grade
Well/moderate 3706 30.4 3651 40.4 3047 30.8
Intermediate/poor 4669 38.3 2790 30.8 4465 45.1
Unknown 3820 31.3 2605 28.8 2388 24.1
SCC, squamous cell carcinoma.
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nocarcinoma and from 11.6% to 18.9% for M0 oesoph-
ageal SCC. No signiﬁcant increase in survival was
detected for M0 gastric cardia carcinoma
(19.0–20.6%). In the metastatic setting, 2-year relative
survival signiﬁcantly increased for oesophageal carci-
noma, but not for gastric cardia carcinoma. Survival
curves are depicted in Fig. 4.
4. Discussion
Worldwide, the incidence of oesophageal cancer is
increasing. In the United States, the incidence of
oesophageal cancer has shown a sixfold rise over the last
three decades.4 This is entirely caused by a rise in the
incidence of oesophageal adenocarcinoma, primarily in
white males.3 In Europe, mainly the Northern part,
there has also been an increase in the incidence of
oesophageal adenocarcinoma in men, but not in
women.5 The incidence of SCC has remained stable in
Europe and the United States.3,5 In the current study,
similar patterns were found. The incidence of oesopha-
geal adenocarcinoma in males showed a threefold
increase over two decades (1989–2008), with a smaller
increase in females. For SCC, the incidence remained
constant in males, and slightly increased in females,
who increased their smoking habits over the past
decades.
For gastric adenocarcinoma, there has been a world-
wide decrease in the incidence of non-cardia gastric
cancer over the past decades.17,18 For gastric cardia can-
cer, early studies report an increasing incidence in theWest Midlands (England),19 Connecticut (US),20 and
the SEER regions (US),21 but none of these studies
report data after 1989. More recent studies from the
United States,4,7 Sweden,22 and Spain23 conﬁrmed this
increase until the early nineties, after which the
incidence for gastric cardia cancer reached a plateau
followed by a slow decrease as of the late nineties. Other
studies, including the current study, report a stable or
decreasing incidence of gastric cardia cancer over the
last decades.24,25 Therefore, the often cited17,26,27
increasing incidence of cardia gastric cancer in devel-
oped countries should be considered carefully, and be
judged in the light of more recent observations.
In the current study, incidence rates signiﬁcantly
changed over time for adenocarcinoma of the oesopha-
gus in both males and females, for SCC in females and
for gastric cardia carcinoma in males. Time trends in
disease incidence should be interpreted cautiously,
because they might reﬂect changes in diagnostics or
reclassiﬁcation of tumours, rather than representing a
true change in disease burden. With the reﬁnement of
various diagnostic modalities in general, and the
increased use of endoscopy in patients with reﬂux
disease or Barret’s oesophagus, improved diagnosis
might be a reason for the increased incidence of oesoph-
ageal adenocarcinoma in the Netherlands. However,
improved diagnosis would be present in all disease enti-
ties, in both sexes and throughout the entire oesophagus
in a comparable way. Furthermore, improved diagnosis
would mainly lead to an increased incidence of early
stage tumours, but this is not observed in the current
study.
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Fig. 2c. Stage distribution of gastric cardia adenocarcinoma in the
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Fig. 2a. Stage distribution of oesophageal adenocarcinoma in the
Netherlands, 1989–2008.
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reclassiﬁcation. Because there are no clear morphologic
diﬀerences that distinguish adenocarcinomas of the
lower oesophagus from those of the cardia, tumours of
the gastro-oesophageal junction are vulnerable to
reclassiﬁcation. And although the registry’s topography
classiﬁcation rules have remained unchanged over theF
thstudy period, clinical classiﬁcation of tumours of the
gastro-oesophageal junction might have shifted towards
oesophageal cancer. However, the sixfold increase in the
incidence of oesophageal adenocarcinoma is not fully
compensated for by the decrease in gastric cardia
adenocarcinomas. Furthermore, reclassiﬁcation would
be equally present in males and females. Therefore,
although reclassiﬁcation might partly explain the
increase in oesophageal adenocarcinoma, it is likely that
the greater part of the increase in oesophageal adenocar-
cinoma is a true rise in disease burden.
All three studied cancers have their speciﬁc etiologic
factors. Oesophageal adenocarcinoma has been associ-
ated with obesity,28 smoking,21 GORD,29 Barrett’s
oesophagus,30 high meat consumption,31 and a high
fat consumption,31 whereas oesophageal SCC has been
associated with alcohol consumption,21 smoking,21 and
low fruit intake.32 For gastric cardia adenocarcinoma,
risk factors are male sex and white race,33 obesity,28
GORD,34 meat consumption,31 and fat consumption.31
These risk factors show a signiﬁcant overlap with the
risk factors for oesophageal adenocarcinoma, making
it diﬃcult to explain why incidence changes for oesoph-
ageal and gastric cardia adenocarcinoma are discordant.
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Fig. 3. Relative distribution of location for oesophageal carcinoma.
(a) Adenocarcinoma and (b) squamous cell carcinoma.
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diﬀerent histopathologic entities but evidence for this is
limited.35
Others have favoured the hypothesis that gastric
cardia cancer consists of two distinct aetiologies: one
arising from Helicobacter pylori associated severe
atrophic gastritis and being of intestinal or diﬀuse sub-
type similar to non-cardia cancer, and one related to
GORD and intestinal in subtype, similar to oesophageal
adenocarcinoma.34 With a decreasing incidence ofTable 2a
5-Year relative survival of non-metastatic (M0) oesophageal and cardia ca
Oesophageal adenocarcinoma (%)
1989–1993 12.2 (10.0–14.6)
1994–1998 14.9 (13.0–16.9)
1999–2003 17.4 (15.8–19.2)
2004–2008 25.3 (22.9–27.8)
95% conﬁdence intervals in parentheses.
Table 2b
2-Year relative survival of metastatic (M1) oesophageal and cardia carcino
Oesophageal adenocarcinoma (%)
1989–1993 3.3 (1.8–5.7)
1994–1998 5.3 (3.7–7.3)
1999–2003 5.7 (4.5–7.1)
2004–2008 9.0 (7.7–10.4)
95% conﬁdence intervals in parentheses.H. pylori, the ﬁrst subtype might be responsible for the
decreasing incidence of cardia carcinoma.9 Although
this might be a plausible explanation, underlying mech-
anisms for the diﬀerences in incidence trends need fur-
ther investigation before deﬁnite conclusions can be
drawn.
For both M0 and M1 oesophageal cancer, relative
survival rates improved during the study period. For
M0 tumours, this may be the result of centralisation
of oesophageal cancer surgery in the Netherlands. Cen-
tralisation improves patient selection, perioperative
care, surgical experience and decreases failure to rescue
in case of complications. As of 2006, a yearly minimum
of 10 oesophagectomies per hospital was enforced by
the Dutch Health Care Inspectorate. In two regions
of the Netherlands, the minimum volume was intro-
duced earlier, signiﬁcantly improving survival.36
Secondly, the increased use of neoadjuvant chemother-
apy or chemoradiation might have contributed to the
better survival rates for M0 oesophageal cancer.37,38
From 2004 to 2008, a large Dutch multicentre trial
has explored the use of preoperative chemoradiation
in oesophageal cancer.39 All patients in this trial were
included in the current analysis. For M1 tumours,
the increase in survival can be attributed to stage
migration due to improved detection of distant
metastases.
A very recent study shows that oesophagectomies
were centralised to a great extent over the past 20 years
in the Netherlands, while most gastrectomies are
performed in low volume centres. High volume oeso-
phagectomies were associated with lower postoperative
mortality, while there were hardly any high volume
gastrectomies to conduct a properly powered volume-
outcome analysis for gastrectomy (Dikken et al., unpub-
lished). Furthermore, in the study period multimodality
therapy has been administered more frequently inrcinoma in the Netherlands, 1989–2008
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Fig. 4. Relative survival of patients with oesophageal and gastric cardia carcinoma in the Netherlands, 1989–2008. Relative survival estimates and
conﬁdence intervals are shown in Table 2. (a) Oesophageal adenocarcinoma, M0; (b) oesophageal adenocarcinoma, M1; (c) oesophageal squamous
cell carcinoma, M0; (d) oesophageal squamous cell carcinoma, M1; (e) cardia adenocarcinoma, M0; and (f) cardia adenocarcinoma, M1.
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not shown). This might explain why for gastric cardia
cancer, relative survival did not signiﬁcantly increase,
corresponding with earlier results from one region in
the Netherlands.40 Because postoperative chemoradio-
therapy and perioperative chemotherapy have emerged
as adjuvant strategies that improve outcome in gastric
cancer, it is expected that survival will increase over
the coming decades.
In conclusion, the current manuscript reveals an
increase in the incidence of oesophageal adenocarcinoma
both in males and females, and a decrease in the inci-
dence of gastric cardia adenocarcinoma in males. These
are most likely true changes in disease burden, rather
than being caused by either improved diagnosis or reclas-
siﬁcation. The question why incidence trends for oesoph-
ageal and cardia adenocarcinoma are diﬀerent remains
to be elucidated, but the existence of two diﬀerent types
of gastric cardia cancer is a possible explanation.
The improved survival forM0 oesophageal carcinoma
reﬂects an increasing number of oesophagectomies per-
formed in high-volume centres, and the increased use
of modern multi-modality therapy. These two factors
are poorly acknowledged in treating gastric cancer in
the Netherlands, which might explain why no signiﬁcant
increase in survival was detected in this tumour type.
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